Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

AbbVie and Cugene partner to tackle autoimmune diseases

2nd Annual mRNA-Based Therapeutics Summit

BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone

Do pharmaceutical businesses need to rethink what their graduate schemes offer?

AstraZeneca extends oncology partnership with Proteros

ALL

NICE1

Cancer/ News/ UK & Europe

Pfizer objects to NICE methods in leukaemia drug rejection

Richard Staines ALL, blood cancer, leukaemia, market access, NICE, Pfizer 0 Comment

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the

X

Pfizer objects to NICE methods in leukaemia drug rejection

https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

Richard Staines ALL, blood cancer, cancer, Pfizer, UCB 0 Comment

Antibody-drug conjugate with FDA gets six-month review.

X

Pfizer’s fast-tracked leukaemia candidate could rival CAR-Ts

https://pharmaphorum.com/news/pfizer-files-leukaemia-antibody-us/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone
AstraZeneca extends oncology partnership with Proteros
Novel drug to tackle inflammatory diseases begins trial

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com